Prospective memory deficit associated with major depressive disorder: Causality, clinical impact, and potential molecular mechanisms
< 0.05). Among 134 patients with follow-up, linear mixed-effects models revealed slower HAMD reduction in patients with PM deficits (z = 2.287, P = 0.022). PM performance showed no significant change after treatment (P = 0.117). To investigate potential mechanisms and therapeutics, shared targets for MDD and PM were identified through network pharmacology and summary-data-based MR, revealing Rap1 signaling as the top enriched pathway with eight core targets. Molecular docking showed relatively weak predicted affinities (mean > -7.5 kcal/mol) of commonly used antidepressants to these targets. Virtual screening of psychiatric compounds identified Hypericin, with strong affinity to the core targets (mean -9.06 kcal/mol). In conclusion, MDD may increase the risk of PM deficits, which are associated with poorer treatment response and show limited improvement following current antidepressant treatments. Rap1-related mechanisms may be involved, and Hypericin may be considered a compound for further investigation.
Authors
- Xu Han (ORCID: https://orcid.org/0000-0003-0662-882X)
- Qidi Diao
- Yan Wang (ORCID: https://orcid.org/0000-0002-0066-6465)
- Kun Zhang (ORCID: https://orcid.org/0000-0001-5696-2426)
- Yufei Ma
- Junyuan Sun
- Lei Hu
- Weihua Yue
- Kai Zhang
- Yihan Ma
- Jiani Li
- Xinyun Yuan
Institutions
- Shandong University (CN)
- Peking University (CN)
- Shandong Mental Health Center (CN)
- Affiliated Hospital of Jining Medical University (CN)
- Peking University Sixth Hospital (CN)
- Jining Medical University (CN)
Publication Details
- Journal
- Neurotherapeutics
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1016/j.neurot.2026.e01115
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Beijing Nova Program